Details for Patent: 8,143,241

Which drugs does patent 8,143,241 protect, and when does it expire?

Patent 8,143,241 protects LYNPARZA, ZEJULA, AKEEGA, and RUBRACA, and is included in six NDAs.

This patent has eighty-six patent family members in thirty-eight countries.

Summary for Patent: 8,143,241

Title:	DNA damage repair inhibitors for treatment of cancer
Abstract:	The present invention relates to the recognition that inhibition of the base excision repair pathway is selectively lethal in cells which are deficient in HR dependent DNA DSB repair. Methods and means relating to the treatment of cancers which are deficient in HR dependent DNA DSB repair using inhibitors which target base excision repair components, such as PARP, is provided herein.
Inventor(s):	Alan Ashworth, Stephen Jackson, Niall Martin, Graeme Smith, Mark O'Connor
Assignee:	Institute of Cancer Research Royal Cancer Hospital , Kudos Pharmaceuticals Ltd
Application Number:	US11/245,735
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,143,241
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 8,143,241

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Astrazeneca	LYNPARZA	olaparib	CAPSULE;ORAL	206162-001	Dec 19, 2014		DISCN	Yes	No						TREATMENT OF BRCA MUTATED OVARIAN CANCER USING PARP INHIBITOR
Glaxosmithkline	ZEJULA	niraparib tosylate	CAPSULE;ORAL	208447-001	Mar 27, 2017		DISCN	Yes	No						A METHOD OF TREATMENT OF ADVANCED OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER ASSOCIATED WITH HOMOLOGOUS RECOMBINATION DEFICIENCY (HRD) POSITIVE STATUS
Janssen Biotech	AKEEGA	abiraterone acetate; niraparib tosylate	TABLET;ORAL	216793-001	Aug 11, 2023		RX	Yes	No						A METHOD FOR TREATING METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC), WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA-MUTATION
Janssen Biotech	AKEEGA	abiraterone acetate; niraparib tosylate	TABLET;ORAL	216793-001	Aug 11, 2023		RX	Yes	No						A METHOD FOR TREATING METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC), WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA2-MUTATION
Janssen Biotech	AKEEGA	abiraterone acetate; niraparib tosylate	TABLET;ORAL	216793-002	Aug 11, 2023		RX	Yes	Yes						A METHOD FOR TREATING METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC), WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA-MUTATION
Janssen Biotech	AKEEGA	abiraterone acetate; niraparib tosylate	TABLET;ORAL	216793-002	Aug 11, 2023		RX	Yes	Yes						A METHOD FOR TREATING METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC), WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA2-MUTATION

International Family Members for US Patent 8,143,241

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1633724		C300726	Netherlands
European Patent Office	1633724		CR 2015 00012	Denmark
European Patent Office	1633724		C20150012 00136	Estonia
European Patent Office	1633724		92680	Luxembourg
European Patent Office	1633724		PA2015016	Lithuania
European Patent Office	1633724		15C0022	France